Novo Nordisk and Valo to research cardiometabolic treatments

Spread the love

STOCKHOLM (Reuters) – Danish drugmaker Novo Nordisk said on Monday it would collaborate with U.S. tech firm Valo Health to discover and develop new treatments for cardiometabolic diseases using human data and artificial intelligence.

Novo Nordisk said in a statement it will use Valo’s platform and Valo will receive an upfront payment and a potential near-term milestone payment of $60 million.

Valo is also eligible to receive milestone payments for up to 11 programmes, totalling up to $2.7 billion, plus research and development funding and potential royalty payments, Novo said.

(Reporting by Anna Ringstrom, editing by Terje Solsvik)

EMEA Tribune is not involved in this news article, it is taken from our partners and or from the News Agencies. Copyright and Credit go to the News Agencies, email [email protected] Follow our WhatsApp verified Channel210520-twitter-verified-cs-70cdee.jpg (1500×750)

Support Independent Journalism with a donation (Paypal, BTC, USDT, ETH)

News Agencies

About Author

The latest news from the News Agencies

You may also like

Saudi Arabia imposes curfew

Saudi Arabia imposes curfew due to coronavirus in Makkah and Madina

Spread the loveSaudi Arabia’s government has decided to impose a 24-hour curfew in Makkah and Madina while tightening precautionary measures
saudi royal family

Dozens of Saudi royal family infected with coronavirus: report

Spread the loveRiyadh: 150 members of the Saudi royal family have been diagnosed with Coronavirus.   According to a US